Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search


Veracyte is a diagnostics company offering genomic tests services

Veracyte is a company that is creating solutions to improve traditional diagnostic methods and clinical outcomes for patients. The company was founded in 2008, in San Francisco, California, United States.

The company has developed genomic diagnostic tests that are designed to provide physicians and patients with paths forward. Their tests are equipped with machine learning that provides diagnostics, prognostic and treatment options. The tests can be used to determine what a patient should do after diagnosed with thyroid cancer, lung cancer, breast cancer, and idiopathic pulmonary fibrosis.

Veracyte has developed their products Afirma, Percepta, Envisia, and Prosigna to reduce uncertainties and risks in diagnostics. Afirma is a genomic sequencing classifier that was developed with RNA whole-transcriptome sequencing and machine learning, and was designed to identify benign thyroid nodules. Percepta is also a genomic sequencing classifier, and identifies lung cancer. Prosignia uses genomic technology to identify breast cancer and the make-up of a patient's disease. Envisia is Veracyte's product that diagnoses idiopathic pulmonary fibrosis.


April 28, 2021
Veracyte announces the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier , a novel genomic test, in helping to improve lung cancer diagnosis.
February 5, 2021
Veracyte raises a $550,000,000 venture round.
November 17, 2020
Veracyte announces new general manager structure to advance global expansion.

March 29, 2016
Veracyte raises a $45,000,000 venture round from Visium Healthcare Partners.
July 2013
Veracyte raises a $28,000,000 series A round from Domain Associates, GE Ventures, Kleiner Perkins Caufield & Byers and Versant Ventures.
June 11, 2010
Veracyte raises a $28,000,000 series B round from Domain Associates, Kleiner Perkins Caufield & Byers and Versant Ventures.
December 21, 2006
Veracyte raises a $300,000 series A round.

Funding rounds


Further Resources



Conor Hale
October 11, 2021
The company also delivered recent findings that showed the Percepta genomic test's ability to more accurately separate groups of patients based on their risk of developing tumors from suspicious lung nodules.
July 8, 2021
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion - read this article along with other careers information, tips and advice on BioSpace
July 1, 2021
Veracyte hat expand and further strengthen the company's medical team. William A. Bulman, M.D. and Paul Kelly Marcom, M.D, have joined the company as medical director for Lung Cancer and medical director for Breast Cancer, respectively.
June 29, 2021
Eikon Therapeutics, Inc. today announced that it has named Alfred "Freddie" Bowie, Jr, PhD, to the newly created position of Chief Financial Officer.
Conor Hale
June 14, 2021
Just three months ago, Veracyte laid out $600 million to buy Decipher Biosciences and its genomic prostate cancer test. Now, that diagnostic has racked up new data showing it can help identify patients most likely to benefit from specific drugs.


Golden logo
By using this site, you agree to our Terms & Conditions.